Richter Gedeon reports 13% 2005 sales growth

13 February 2006

Hungarian drugmaker Richter Gedeon says that consolidated sales for full-year 2005 grew 12.7% year-on-year to 168.34 billion forint ($806.2 million), on strong sales in the Commonwealth of Independent States.

During the period, operating profit rose 4.8% to 38.58 billion forint and operating margins were comparable to the previous year's at 22.9% versus 24.6%, while the group's diluted earnings rose 12.2% to 2,403 forint per share as net profit reached $44.71 billion forint.

EU sales decline while CIS booms

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight